Dyadic International Secures Lucrative Biotech Licensing Deal
Company Announcements

Dyadic International Secures Lucrative Biotech Licensing Deal

An announcement from Dyadic International (DYAI) is now available.

Dyadic International, Inc. has struck a deal with Proliant Health and Biologicals to license its cutting-edge fungal production technology for manufacturing recombinant serum albumin. Dyadic stands to gain an initial $500,000, another half a million upon successful production strain transfer, and an additional $500,000 upon achieving a specified productivity level. Moreover, Dyadic will earn a share of the profits from Proliant’s sales of the animal-free product, marking a significant milestone in both companies’ commercial endeavors.

Find detailed analytics on DYAI stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskDyadic International Aligns CFO Incentives with Performance
Catie PowersIs DYAI a Buy, Before Earnings?
TipRanks Auto-Generated NewsdeskDyadic International Strikes Major Biotech Deal with Proliant
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App